ホルモン受容体陽性HER2陰性転移性乳がんに対する内分泌療法不応後のパルボシクリブ（PD-0332991）とフルベストラントの併用療法（PALOMA-3）

基本情報

NCT ID

NCT01942135

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

521

治験依頼者名

Pfizer

概要

The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the superiority of palbociclib in combination with fulvestrant (Faslodex®) over fulvestrant alone in prolonging PFS in women with HR+, HER2 negative metastatic breast cancer whose disease has progressed after prior endocrine therapy. The safety between the two treatment arms will also be compared. During study treatment, pre- and perimenopausal women must be receiving therapy with the LHRH agonist goserelin (Zoladex® or generic).

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)